Drug intelligence / Profile preview

EXS4318

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules

Overview

EXS4318 is a potentially first-in-class, potent and selective small molecule inhibitor of protein kinase C theta (PKC theta), developed for immunology and inflammation indications. It was designed by Exscientia using an AI-driven platform to achieve high potency and selectivity against PKC theta while minimizing off-target effects on related kinases. The compound was in-licensed by Bristol Myers Squibb in August 2021, which now oversees its clinical and commercial development. PKC theta plays a critical role in T cell function and is implicated as a key driver of several autoimmune diseases. As of 2024, EXS4318 has entered Phase 1 clinical trials in the United States for immune system diseases and inflammatory conditions[1][2][3][5][7].

Other names: PKC-theta inhibitor

Targets

PRKCQ (Protein kinase C theta)

Beyond the preview

Go deeper on EXS4318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXS4318.

Explore the full profile